%0 Journal Article
%T Pilot Study Evaluating the Use of a Commercially Available Oral Nutritional Supplement in the Management of Chronic Kidney Disease in Cats
%A Crystal M. Cooley
%A Jessica M. Quimby
%A Stacie Summers
%A Michael R. Lappin
%J Open Journal of Veterinary Medicine
%P 7-17
%@ 2165-3364
%D 2022
%I Scientific Research Publishing
%R 10.4236/ojvm.2021.122002
%X Purpose: To determine if cats with chronic kidney disease (CKD) would
willingly consume an oral nutritional supplement formula (NS-CKD) and to assess
associated effects on select clinical and biochemical parameters. Methods: Client-owned cats with CKD classified as
International Renal Interest Society (IRIS) stage 2 (n = 7), IRIS stage 3 (n =
12), or IRIS stage 4 (1 cat) were classified by the owners as having normal or
variable appetites. The cats were offered 30 ml NS-CKD
for 14 days concurrently with a meal in a separate bowl and the amount of the NS-CKD
consumed daily was recorded. Bodyweight, physical examination, and serum
biochemical profiles were assessed on Days 0, 7, and 14. Results: Greater than
50% of the NS-CKD was consumed by 14 of 20 (70%) cats and 12 of 20 cats (60%)
consumed >80% of the NS-CKD. The total volume of NS-CKD consumed
over the course of the study was statistically
greater for the cats classified by owners as having normal appetite (P =
0.046). Increases in body weight were noted for 9 of 14 cats (64.3%) that ingested >50% of the NS-CKD and 1 of 6 cats (16.7%), that ingested ¡Ü 50% (p = 0.1409) and the group mean %